基于神经递质图谱的卒中后抑郁患者个体化诊疗探索——2例病例报道

doi:10.3969/j.issn.1673-5765.2026.01.012

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (1): 105-112.DOI: 10.3969/j.issn.1673-5765.2026.01.012

基于神经递质图谱的卒中后抑郁患者个体化诊疗探索——2例病例报道

张之婕^1，2，张华²，卫景沛²，钱勋琦^1，2，赵子珺²

1北京 100029 北京中医药大学第一临床医学院
2北京 100029 北京中医药大学东直门医院神经内科

收稿日期:2025-06-24 修回日期:2025-12-19 接受日期:2025-12-29 出版日期:2026-01-20 发布日期:2026-01-20
通讯作者: 赵子珺 drzhaozijun@163.com
基金资助:
中央高水平中医医院临床科研业务费资助（DZMG-QNHB009）

Exploring Individualized Diagnosis and Treatment for Post-Stroke Depression Based on Neurotransmitter Atlas: A Report of Two Cases

ZHANG Zhijie^1,2, ZHANG Hua², WEI Jingpei², QIAN Xunqi^1,2, ZHAO Zijun²

1The First School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China 2Department of Neurology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100029, China

Received:2025-06-24 Revised:2025-12-19 Accepted:2025-12-29 Online:2026-01-20 Published:2026-01-20
Contact: ZHAO Zijun, E-mail: drzhaozijun@163.com

摘要/Abstract

摘要： 卒中后抑郁（post-stroke depression，PSD）患者体内的5-羟色胺（5-hydroxytryptamine，5-HT）水平常显著下降，这一变化与卒中病灶对神经通路的破坏及代谢异常等因素密切相关。5-羟色胺选择性再摄取抑制剂（serotonin-selective reuptake inhibitors，SSRIs），如舍曲林，可选择性抑制突触前膜5-HT再摄取，提高突触间隙5-HT浓度，是目前抗抑郁治疗的一线药物。本病例报道2例缺血性PSD患者，通过分子影像学技术，将其病灶与受累核团映射至5-HT受体/转运体密度图谱，据此区分出突触前与突触后损伤两种亚型，结果显示2例患者分别为突触前及突触后损伤，提示不同PSD亚型可能对舍曲林抗抑郁治疗存在差异反应。本病例报道为探索PSD精准诊断分型及个体化治疗策略提供了新思路。

关键词: 缺血性卒中; 卒中后抑郁; 神经递质映射; 分子影像学; 病例报道

Abstract: Post-stroke depression (PSD) patients often exhibit significantly reduced 5-hydroxytryptamine (5-HT) levels. This alteration is closely associated with stroke-induced disruption of neural pathways and metabolic abnormalities. Serotonin-selective reuptake inhibitors (SSRIs), such as sertraline, the first-line antidepressant drugs, selectively inhibit presynaptic 5-HT reuptake, thereby increasing synaptic 5-HT concentrations. This case report describes two cases of ischemic PSD. Using molecular imaging techniques, the stroke lesions and affected nuclei were mapped onto 5-HT receptor/transporter density atlases, and accordingly identified presynaptic and postsynaptic injury subtypes. The results showed that the two patients presented with presynaptic injury and postsynaptic injury, respectively, suggesting that different PSD subtypes may exhibit differential response to sertraline in antidepressant treatment. This case report provides novel insights for developing precise diagnostic subtypes and individualized treatment strategies for PSD.

Key words: Ischemic stroke; Post-stroke depression; Neurotransmitter mapping; Molecular imaging; Case report

中图分类号:

张之婕, 张华, 卫景沛, 钱勋琦, 赵子珺. 基于神经递质图谱的卒中后抑郁患者个体化诊疗探索——2例病例报道[J]. 中国卒中杂志, 2026, 21(1): 105-112.

ZHANG Zhijie, ZHANG Hua, WEI Jingpei, QIAN Xunqi, ZHAO Zijun. Exploring Individualized Diagnosis and Treatment for Post-Stroke Depression Based on Neurotransmitter Atlas: A Report of Two Cases[J]. Chinese Journal of Stroke, 2026, 21(1): 105-112.

参考文献

[1] 梅峰，孙树印，张作记，等. 5-羟色胺系统与卒中后抑郁[J]. 中华行为医学与脑科学杂志，2015，24（4）：360-363.
MEI F，SUN S Y，ZHANG Z J，et al. Serotonin system and post-stroke depression[J]. Chin J Behav Med & Brain Sci，2015，24（4）：360-363.
[2] VILLA R F，FERRARI F，MORETTI A. Post-stroke depression：mechanisms and pharmacological treatment[J/OL]. Pharmacol Ther，2018，184：131-144[2025-12-10]. https://doi.org/10.1016/j.pharmthera.2017.11.005.
[3] MASUCCIO F G，GRANGE E，DI GIOVANNI R，et al. Post-stroke depression in older adults：an overview[J]. Drugs Aging，2024，41（4）：303-318.
[4] MAYBERG H S，ROBINSON R G，WONG D F，et al. PET imaging of cortical S2 serotonin receptors after stroke：lateralized changes and relationship to depression[J]. Am J Psychiatry，1988，145（8）：937-943.
[5] O’SULLIVAN M J，OESTREICH L K L，WRIGHT P，et al. Cholinergic and hippocampal systems facilitate cross-domain cognitive recovery after stroke[J]. Brain，2022，145（5）：1698-1710.
[6] FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke（FOCUS）：a pragmatic，double-blind，randomised，controlled trial[J]. Lancet，2019，393（10168）：265-274.
[7] LEGG L A，RUDBERG A S，HUA X，et al. Selective serotonin reuptake inhibitors（SSRIs）for stroke recovery[J/OL]. Cochrane Database Syst Rev，2021，11（11）：CD009286[2025-12-10]. https://doi.org/10.1002/14651858.CD009286.pub4.
[8] KALBOUNEH H M，TOUBASI A A，ALBUSTANJI F H，et al. Safety and efficacy of SSRIs in improving poststroke recovery：a systematic review and meta-analysis[J/OL]. J Am Heart Assoc，2022，11（13）：e025868[2025-12-10]. https://doi.org/10.1161/JAHA.122.025868.
[9] ALVES P N，NOZAIS V，HANSEN J Y，et al. Neurotransmitters’ white matter mapping unveils the neurochemical fingerprints of stroke[J/OL]. Nat Commun，2025，16：2555[2025-12-10]. https://doi.org/10.1038/s41467-025-57680-2.
[10] CAMPBELL B C V，MITCHELL P J，KLEINIG T J，et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med，2015，372（11）：1009-1018.
[11] BRUGNARA G，HERWEH C，NEUBERGER U，et al. Dynamics of cerebral perfusion and oxygenation parameters following endovascular treatment of acute ischemic stroke[J/OL]. J Neurointerv Surg，2022，14（1）：neurintsurg-2020-017163[2025-12-10]. https://doi.org/10.1136/neurintsurg-2020-017163.
[12] DAWS L C. Unfaithful neurotransmitter transporters：focus on serotonin uptake and implications for antidepressant efficacy[J]. Pharmacol Ther，2009，121（1）：89-99.
[13] ZHANG M M. Recent advances in studies of 5-HT autoreceptors and related transporters[J/OL]. Highlights in Science，2023，65：62-67[2025-12-10]. https://doi.org/10.54097/hset.v65i.11235.
[14] 汪玫，瞿金涛，吴爱群. 选择性5-羟色胺再摄取抑制剂不良反应的研究进展[J]. 实用医学杂志，2010，26（14）：2656-2658.
WANG M，QU J T，WU A Q. Research progress on adverse reactions of selective serotonin reuptake inhibitors[J]. The Journal of Practical Medicine，2010，26（14）：2656-2658.
[15] VAHID-ANSARI F，ZHANG M，ZAHRAI A，et al. Overcoming resistance to selective serotonin reuptake inhibitors：targeting serotonin，serotonin-1A receptors and adult neuroplasticity[J/OL]. Front Neurosci，2019，13：404[2025-12-10]. https://doi.org/10.3389/fnins.2019.00404.
[16] SHARP T，UMBERS V，GARTSIDE S E. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1a and 5-HT1b receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo[J]. Br J Pharmacol，1997，121（5）：941-946.
[17] BYMASTER F P，CALLIGARO D O，FALCONE J F，et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine[J]. Neuropsychopharmacology，1996，14（2）：87-96.
[18] XUE X B，SONG Y，YU X J，et al. Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants：a randomized controlled trial[J/OL]. Medicine（Baltimore），2018，97（8）：e9786[2025-12-10]. https://doi.org/10.1097/MD.0000000000009786.
[19] MAREK G J，CARPENTER L L，MCDOUGLE C J，et al. Synergistic action of 5-HT2a antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders[J]. Neuropsychopharmacology，2003，28（2）：402-412.
[20] ROBINSON R G，KUBOS K L，STARR L B，et al. Mood disorders in stroke patients. Importance of location of lesion[J]. Brain，1984，107（Pt 1）：81-93.
[21] SHIMMYO K，OBAYASHI S. Fronto-cerebellar diaschisis and cognitive dysfunction after pontine stroke：a case series and systematic review[J/OL]. Biomedicines，2024，12（3）：623[2025-12-10]. https://doi.org/10.3390/biomedicines12030623.

基于神经递质图谱的卒中后抑郁患者个体化诊疗探索——2例病例报道

Exploring Individualized Diagnosis and Treatment for Post-Stroke Depression Based on Neurotransmitter Atlas: A Report of Two Cases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	熊云云, 路正钊, 马瑛, 单大卫, 吴娜, 郝曼均, 马宇洁, 武双喆, 李祉馨, 沈柯佳, 唐奕哲, 王拥军. 卒中：回眸2025[J]. 中国卒中杂志, 2026, 21(1): 1-23.
[2]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[3]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.
[4]	何丹丹, 冯宝玉, 刘改芬, 谷鸿秋, 李姝雅. 中性粒细胞与淋巴细胞比值对急性缺血性卒中静脉溶栓患者预后的预测价值：基于3项随机对照试验的个体患者数据分析[J]. 中国卒中杂志, 2026, 21(1): 38-47.
[5]	赵敏, 冯宝玉, 何丹丹, 王维聪, 李姝雅. 瑞替普酶与阿替普酶治疗急性缺血性卒中合并心律失常患者的有效性及安全性比较[J]. 中国卒中杂志, 2026, 21(1): 48-54.
[6]	何丹丹, 李姝雅. 急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展[J]. 中国卒中杂志, 2026, 21(1): 55-64.
[7]	殷子欣, 鲁珊珊, 施海彬, 吴飞云, 许晓泉. 不同期相CTA脑静脉引流对急性缺血性卒中患者血管内治疗后短期预后的预测价值[J]. 中国卒中杂志, 2026, 21(1): 70-77.
[8]	班淇琦, 王苇, 郭远, 厉阳, 苏星月, 瞿航. 构建目标检测模型在NCCT上检测急性小面积梗死灶的研究[J]. 中国卒中杂志, 2026, 21(1): 78-87.
[9]	中国卒中学会, 《单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识》专家组. 单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识[J]. 中国卒中杂志, 2026, 21(1): 88-98.
[10]	刘思晓, 吴伟, 冯硕, 范予湉, 王伟, 梁继业. 带状疱疹后大血管病变致脑梗死1例[J]. 中国卒中杂志, 2026, 21(1): 99-104.
[11]	王逸聪, 李季锦, 陈玮琪, 濮月华, 廖晓凌, 周衡, 曲辉, 王伊龙. 永存三叉动脉合并缺血性卒中1例报道[J]. 中国卒中杂志, 2026, 21(1): 113-117.
[12]	栾伟, 魏达, 马超, 张华伟, 李铁民, 彭玉涛, 刘长青. 侵入性迷走神经电刺激联合康复训练治疗缺血性卒中后上肢运动功能障碍的可行性、疗效与安全性研究[J]. 中国卒中杂志, 2025, 20(9): 1097-1103.
[13]	解正绮, 宋晓微. ICAS所致急性缺血性卒中的斑块特征与发病机制关系研究[J]. 中国卒中杂志, 2025, 20(9): 1104-1112.
[14]	柴昌, 胡全忠. 红细胞压积与海拔梯度对中高海拔地区轻型缺血性卒中患者卒中后睡眠障碍的影响研究[J]. 中国卒中杂志, 2025, 20(9): 1113-1120.
[15]	苗连海, 陈继群, 宋诗涛, 杨志勇, 赵辉. 基于GDS-15评价老年卒中后抑郁状态的影响因素及其纵向分析[J]. 中国卒中杂志, 2025, 20(9): 1131-1136.